Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Verastem selects LabCorp for CDx partner
February 2013
SHARING OPTIONS:

CAMBRIDGE, Mass.Verastem Inc. and Laboratory Corporation of America Holdings (LabCorp) have inked an agreement for the validation of biomarkers for VS-6063, Verastem's lead focal adhesion kinase inhibitor, in the development of a companion diagnostic. The biomarkers will be tested in clinical studies in patients with ovarian cancer and mesothelioma, including a VS-6063 mesothelioma study expected to begin this year. The compound is designed to target and kill cancer stem cells through the inhibition of FAK signaling.  
 
"We believe the approximately 50 percent of mesothelioma patients lacking merlin may be particularly responsive to treatment with FAK inhibitors," Dan Paterson, Verastem's vice president, head of Corporate Development and Diagnostics, said in a statement. "LabCorp is the perfect partner to progress our research on merlin into a companion diagnostic for VS-6063."  
 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.